Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis
| Autor: | Gian Marco Tosi, Bruno Frediani, Vincenzo Venerito, Silvana Guerriero, Antonio Vitale, Luca Cantarini, Mauro Galeazzi, Ida Orlando, Giacomo Emmi, Claudia Fabiani, Fiorella Fusco, Giuseppe Lopalco, Lorenzo Vannozzi, Rossella Franceschini, Florenzo Iannone, Daniela Bacherini, Jurgen Sota |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Drug
Adult Male medicine.medical_specialty Visual acuity media_common.quotation_subject Visual Acuity Behcet's disease Gastroenterology Uveitis Behçet’s disease 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Immunology and Allergy Humans In patient drug retention rate infliximab treatment uveitis Ophthalmology media_common Retrospective Studies 030203 arthritis & rheumatology business.industry Behcet Syndrome Retention rate medicine.disease Infliximab Surgery Treatment Outcome Concomitant Antirheumatic Agents 030221 ophthalmology & optometry Female medicine.symptom business medicine.drug Follow-Up Studies Forecasting |
| Zdroj: | Ocular immunology and inflammation. 27(1) |
| ISSN: | 1744-5078 |
| Popis: | Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behcet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment.Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves.Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|